Grass allergy sufferers wanted for Lundbeck phase I antibody study

In a new phase I study, Lundbeck will test the safety of an antibody it acquired in 2019.

Photo: Thomas Borberg

Recruitment has been initiated for a new phase I study designed to test the safety of a once-monthly injection treatment with the antibody Lu AG09222 in patients with grass pollen allergy, according to a filing on the database Clinical Trials, which collects information about research studies.

Lundbeck does not report any therapeutic targets for the phase I study in the study description, however, allergies and migraines are known to be connected, the latter of which has been a big focus area of Lundbeck ever since it acquired Alder Therapeutics in 2019. In the takeover, Lundbeck also gained access to the preventive migraine treatment Vyepti.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs